Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Youssef

Showing results (21-30 of 41) with videos related to

Pageof 5
Sort By:
International Journal of Rheumatic Diseases|July 22, 2017
Psoriatic arthritis treatment regimens, therapy duration and reasons for cessation in the biologics era: a multi-centre Australian studyKathleen Tymms, Ayano Kelly, Paul Bird, et al.
Clinical and Experimental Rheumatology|May 17, 2024
Real-world utilisation and switching between Janus kinase inhibitors in Australian patients with rheumatoid arthritis in the OPAL datasetSabina Ciciriello, Geoffrey O Littlejohn, Tamas Treuer, et al.
International Journal of Rheumatic Diseases|February 27, 2020
Cranial and large vessel activity on positron emission tomography scan at diagnosis and 6 months in giant cell arteritisAnthony M Sammel, Edward Hsiao, Geoffrey Schembri, et al.
Clinical Rheumatology|April 19, 2018
Treatment patterns among patients with rheumatic disease (rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and undifferentiated arthritis (UnA)) treated with subcutaneous TNF inhibitorsKathleen Tymms, Geoff Littlejohn, Hedley Griffiths, et al.
Frontiers in Digital Health|January 26, 2023
A novel electronic patient-reported outcome delivery system to implement health-related quality of life measures in routine clinical care: An analysis of 5 years of experienceKathleen Tymms, Catherine O'Sullivan, Tegan Smith, et al.
International Journal of Rheumatic Diseases|March 25, 2017
Long-term efficacy and tolerability of mycophenolate mofetil therapy in diffuse scleroderma skin diseaseDaniel Boulos, Gene-Siew Ngian, Anton Rajadurai, et al.
Clinical Rheumatology|July 23, 2020
Performance of the 2017 EUSTAR activity index in an scleroderma cohortLaura Ross, Wendy Stevens, Michelle Wilson, et al.
Rheumatology (Oxford, England)|February 17, 2024
Multiple serum biomarkers associate with mortality and interstitial lung disease progression in systemic sclerosisMatthew James Sinclair Parker, Adelle S Jee, Dylan Hansen, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 9, 2019
Diagnostic Accuracy of Positron Emission Tomography/Computed Tomography of the Head, Neck, and Chest for Giant Cell Arteritis: A Prospective, Double-Blind, Cross-Sectional StudyAnthony M Sammel, Edward Hsiao, Geoffrey Schembri, et al.
Clinical and Experimental Rheumatology|April 7, 2016
Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: results from the Australian Scleroderma Cohort StudyClaire Owen, Gene-Siew Ngian, Kathleen Elford, et al.
Pageof 5

Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
International Journal of Rheumatic Diseases|July 22, 2017
Psoriatic arthritis treatment regimens, therapy duration and reasons for cessation in the biologics era: a multi-centre Australian studyKathleen Tymms, Ayano Kelly, Paul Bird, et al.
Clinical and Experimental Rheumatology|May 17, 2024
Real-world utilisation and switching between Janus kinase inhibitors in Australian patients with rheumatoid arthritis in the OPAL datasetSabina Ciciriello, Geoffrey O Littlejohn, Tamas Treuer, et al.
International Journal of Rheumatic Diseases|February 27, 2020
Cranial and large vessel activity on positron emission tomography scan at diagnosis and 6 months in giant cell arteritisAnthony M Sammel, Edward Hsiao, Geoffrey Schembri, et al.
Clinical Rheumatology|April 19, 2018
Treatment patterns among patients with rheumatic disease (rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and undifferentiated arthritis (UnA)) treated with subcutaneous TNF inhibitorsKathleen Tymms, Geoff Littlejohn, Hedley Griffiths, et al.
Frontiers in Digital Health|January 26, 2023
A novel electronic patient-reported outcome delivery system to implement health-related quality of life measures in routine clinical care: An analysis of 5 years of experienceKathleen Tymms, Catherine O'Sullivan, Tegan Smith, et al.
International Journal of Rheumatic Diseases|March 25, 2017
Long-term efficacy and tolerability of mycophenolate mofetil therapy in diffuse scleroderma skin diseaseDaniel Boulos, Gene-Siew Ngian, Anton Rajadurai, et al.
Clinical Rheumatology|July 23, 2020
Performance of the 2017 EUSTAR activity index in an scleroderma cohortLaura Ross, Wendy Stevens, Michelle Wilson, et al.
Rheumatology (Oxford, England)|February 17, 2024
Multiple serum biomarkers associate with mortality and interstitial lung disease progression in systemic sclerosisMatthew James Sinclair Parker, Adelle S Jee, Dylan Hansen, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 9, 2019
Diagnostic Accuracy of Positron Emission Tomography/Computed Tomography of the Head, Neck, and Chest for Giant Cell Arteritis: A Prospective, Double-Blind, Cross-Sectional StudyAnthony M Sammel, Edward Hsiao, Geoffrey Schembri, et al.
Clinical and Experimental Rheumatology|April 7, 2016
Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: results from the Australian Scleroderma Cohort StudyClaire Owen, Gene-Siew Ngian, Kathleen Elford, et al.
Pageof 5